(redirected from adoptive immunotherapy)
Also found in: Dictionary, Medical, Acronyms, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Words related to immunotherapy

therapy designed to produce immunity to a disease or to enhance resistance by the immune system

Related Words

References in periodicals archive ?
In this trial, standard-risk AML patients and high-risk patients without suitable HSCT donors (or who decline HSCT) were eligible for KIRmis-matched haplo NK cell adoptive immunotherapy.
Parker et al., "A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer," Clinical Cancer Research, vol.
Heslop, "Adoptive immunotherapy for posttransplantation viral infections," Biology of Blood and Marrow Transplantation, vol.
The white blood cells normally used in adoptive immunotherapy have traditionally been collected from patients after they have fallen ill and are invariably affected by the disease or illness which has struck down the whole body.
At The James, research in adoptive immunotherapy is under way for certain patients with advanced colon cancer.
Lee et al., "Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy," Cancer Research, vol.
Schmidt-Wolf, "An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells," Expert Opinion on Biological Therapy, vol.
Rosenberg has been a pioneer in a new treatment called "adoptive immunotherapy," or "cell-transfer therapy."
Adoptive immunotherapy for HCC includes cytokine-induced killer (CIK) cells, tumor-infiltrating lymphocytes (TILs), natural killer (NK) cells, and chimeric antigen receptor (CAR) T cells.
Notably, another study including 5 ACT trials found that levels of peripheral CD4 + Foxp3+ Tregs were negatively associated with clinical response to adoptive immunotherapy in melanoma patients [32].
Lin et al., "Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma," PLoS One, vol.
These data suggested that NK-cell-based adoptive immunotherapy may represent a valuable adjuvant in the treatment of NB patients with metastatic disease, in a minimal residual disease setting [47].
The clinical efficacy of the allogeneic NK cell adoptive immunotherapy to treat solid tumors has also been evaluated by several groups [75-77].
In addition to primary NK cells, also the established NK cell line NK-92 is being developed for adoptive immunotherapy. The NK-92 cell line was established from a 50-year-old male patient with rapidly progressive non-Hodgkin's lymphoma by Gong et al.